Control
Dec 31 2022 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00297-1 | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial |
| 26% lower mortality (p=0.08). RCT 368 mechanically ventilated COVID-19 patients showing lower mortality with vilobelimab. | ||